ADVFN ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
110,98
1,68
( 1,54% )
Aktualisiert: 13:18:59

Gilead Sciences Inc (GIS) Aktie

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Premium

Wichtige Statistiken und Details

Current Price
110,98
( 1,54% )
Gebot
110,04
Fragen
110,78
Volumen
448
110,22 Tagesbereich 110,98
90,01 52-Wochen-Bereich 132,16
Marktkapitalisierung
Handelsende
109,30
Handelsbeginn
110,52
Letzte Trade
31
@
110.98
Letzter Handelszeitpunkt
13:14:48
Finanzvolumen
-
VWAP
-
Durchschnittliches Volumen (3 Mio.)
6.750.094 €
Ausgegebene Aktien
1.241.569.874
Dividendenrendite (LTM)
3,19 (2,50%)
Kurs-Gewinn-Verhältnis
16,83
Gewinn pro Aktie (EPS)
7,35
Erlöse (LTM)
29,74B
Nettogewinn (LTM)
9,22B

Über Gilead Sciences Inc

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV... Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California. Mehr anzeigen

Sektor
Healthcare
Branche
Pharmaceuticals
Website
Hauptsitz
Foster City, United States
Gegründet
1987
Gilead Sciences Inc is listed in the Healthcare sector of the Tradegate (DE) with ticker GIS. The last closing price for Gilead Sciences was 109,30 €. Over the last year, Gilead Sciences shares have traded in a share price range of 90,01 € to 132,16 €.

Gilead Sciences currently has 1.241.569.874 shares in issue. The market capitalisation of Gilead Sciences is 137,79 € billion. Gilead Sciences has a price to earnings ratio (PE ratio) of 16.83.

GIS Neueste Nachrichten

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
13.523.27563744649107.46110.98106.021790108.42504525DE
4-4.34-3.76344086022115.32117.84104.862422109.49835573DE
12-8-6.72381912927118.98122.9104.861921112.33942439DE
265.445.15444381277105.54132.1699.862384117.27798973DE
5216.6217.613395506694.36132.1690.012357108.79964298DE
15639.4455.129997204471.54132.1657.18382784.11515669DE
26054.4896.424778761156.5132.1652.06407376.49014557DE

GIS - Frequently Asked Questions (FAQ)

What is the current Gilead Sciences Inc share price?
The current share price of Gilead Sciences Inc is 110,98 €
How many Gilead Sciences Inc shares are in issue?
Gilead Sciences Inc has 1.241.569.874 shares in issue
What is the market cap of Gilead Sciences Inc?
The market capitalisation of Gilead Sciences Inc is EUR 137,79B
What is the 1 year trading range for Gilead Sciences Inc share price?
Gilead Sciences Inc has traded in the range of 90,01 € to 132,16 € during the past year
What is the PE ratio of Gilead Sciences Inc?
The price to earnings ratio of Gilead Sciences Inc is 16,83
What is the cash to sales ratio of Gilead Sciences Inc?
The cash to sales ratio of Gilead Sciences Inc is 5,17
What is the registered address of Gilead Sciences Inc?
The registered address for Gilead Sciences Inc is 333 Lakeside Drive, Foster City, California, 94404
What is the Gilead Sciences Inc website address?
The website address for Gilead Sciences Inc is www.gilead.com
Which industry sector does Gilead Sciences Inc operate in?
Gilead Sciences Inc operates in the Pharmaceuticals sector

GIS Trades

Mehr

Trades verzögert

Um Echtzeit-Trades zu erhalten, aktualisieren Sie Ihr Konto

Auf Echtzeit aktualisieren
Keine Diskussionen Gefunden.
Neuen Thread Erstellen